Last reviewed · How we verify
NCT03877575: LYS
Lyon Uveitis Study
trial testing No specific intervention. Collection of clinical data in Uveitis in 750 participants. Currently enrolling.
1 January 2025
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 750 |
| Start date | 1 January 2016 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- No specific intervention. Collection of clinical data
Conditions studied
- Uveitis — all drugs for Uveitis →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, any sex, with Uveitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Uveitis or inflammation of the uveal tract results from a heterogeneous collection of disorders of varying etiologies and pathogenic mechanisms. Uveitis is relatively frequent in industrial countries with an estimation of 115 cases for 100 000 persons and is associated with a blindness risk of 10%. Causes of uveitis can be related to different etiologies (infectious, inflammatory or general inflammatory diseases). Therapeutic care is based on ophthalmologic and systemic diagnosis and treatment strategy depends on the severity of inflammation. The main objective of the Lyon uveitis study is to analyze the uveitis ophthalmologic etiology and diagnostic and therapeutic care of the patients. This study is proposed to all patients diagnosed for uveitis and referred to the Department of Internal Medicine of the Croix Rousse hospital, Lyon, france for etiologic diagnosis or treatment. Analysis of i) patients' characteristics, ii) the relevance of complementary exams to determine the uveitis etiology, iii) treatment used. This study will allow a better characterization of the disease on diagnosis practices and therapeutic care.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Long-Term Outcomes of Birdshot Chorioretinopathy Treated with Corticosteroids: A Case Reports.
Ferracci D, Mathis T, Gavoille A, Gerfaud-Valentin M, et al · · 2023 · cited 4× · PMID 37629330 · DOI 10.3390/jcm12165288 -
Etiologies of intermediate uveitis in a tertiary center: an age-oriented medical assessment?
Mansuy P, El-Jammal T, Jacquot R, Mathis T, et al · · 2025 · PMID 41389233 · DOI 10.1186/s12348-025-00563-w -
Hydroxychloroquine in the treatment of sarcoidosis-associated uveitis and idiopathic uveitis
PLAVONIL S, EL-JAMMAL T, JACQUOT R, BERT A, et al · · 2024 · DOI 10.21203/rs.3.rs-4493603/v1
Verify or expand the search:
- PubMed search for NCT03877575
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Uveitis
Currently open trials in the same condition.
- NCT07262437 — Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles · NA · active not recruiting
- NCT07176130 — Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore · active not recruiting
- NCT06974162 — Metagenomics for Ocular Inflammation · recruiting
- NCT06431373 — A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis · Phase 3 · active not recruiting
- NCT06310837 — Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis · NA · active not recruiting
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03877575 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 26 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03877575.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing